Redeye updates its view on Acconeer ahead of the Q3 report (due 27 October).
Q3 7% organic growth and $36m (+1-8% vs expectations) 2023 Guidance unchanged, very wide implicit Q4...
Innofactor’s Q3 results were good and quite as expected despite market headwinds.
Low ICR in 2024e... ...but we see supportive options 2024e P/CEPS at ~13.
We incorporate the MFG divestment... ...which pushes CEPS up by ~30%.
Atria reported Q3 EBIT of EUR 19.3m, 28% (EUR 4.2m) above Refinitiv consensus.
Redeye comments on the first data from the ATLAS-IT-05 trial, a study of the oncolytic molecule LTX-...
Redeye judges that more mature NIPU data, indicating OS and ORR benefits of UV1 addition to double C...
Kvartalsrapporten visar högre hyresintäkter och upprätthållet förvaltningsresultat.
OrderYOYO A/S (“OrderYOYO” or the “Company”) continued the Company’s strong performance in Q3-23, sh...
Redeye comments on the new positive results in triple-negative breast cancer presented at ESMO this ...
Redeye provides a quick comment on Gasporox’s AutoMap agreement worth SEK3m with Weber Maschinenbau ...
Inför rapporten förväntar sig Analysguiden en knapp omsättningstillväxt och viss marginalpress.
Redeye is only making minor adjustments to our forecasts following the Q3 report, which was basicall...
DT reports Q3 results on Oct 27. Q3 results will remain modest, but aviation rebound helps SBU to dr...
Q3: EBITDA NOK 4m - soft but broadly in line with our NOK 5m Customer postponing investment hitting ...
Redeye has updated its estimates for Safeture following the Q3 2023 report.
Redeye thinks the Q3 report from Zwipe was soft with almost no revenues and a negative cash flow hig...
Redeye makes negligible estimate revisions on the back of I-Tech’s strong Q3-figures, posting organi...
Redeye is still optimistic on Powercell’s prospects for the coming years following the Q3 report.
